Association of APOE polymorphism with chronic kidney disease in a nationally representative sample: A Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study

BMC Medical Genetics

Volumn 10, Issue , 2009, Pages 108-

  Chu, Audrey Y ^a   Parekh, Rulan S ^a,b   Astor, Brad C ^a   Coresh, Josef ^a   Berthier Schaad, Yvette ^a,c   Smith, Michael W ^c,d   Shuldiner, Alan R ^e   Kao, Wen H L ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION RATE; HISPANIC; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEGRO; OBESITY; PREVALENCE; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN AMERICANS; ALLELES; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLOMERULAR FILTRATION RATE; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

EID: 70450265385     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-10-108     Document Type: Article

References (56)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1-12. 10.1053/ajkd.2003.50007, 12500213.
2. Satko SG, Freedman BI. The importance of family history on the development of renal disease. Curr Opin Nephrol Hypertens 2004, 13:337-341. 10.1097/00041552-200405000-00012, 15073494.
3. Freedman BI, Satko SG. Genes and renal disease. Curr Opin Nephrol Hypertens 2000, 9:273-277. 10.1097/00041552-200005000-00011, 10847329.
4. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41. 10.1159/000180580, 1244564.
6. Levey AS, Coresh J, Balk E. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137-147.
7. Bochud M, Elston RC, Maillard M. Heritability of renal function in hypertensive families of African descent in the Seychelles (Indian Ocean). Kidney Int 2005, 67:61-69. 10.1111/j.1523-1755.2005.00055.x, 15610228.
8. Fox CS, Yang Q, Cupples LA. Genomewide linkage analysis to serum creatinine, GFR, and creatinine clearance in a community-based population: the Framingham Heart Study. J Am Soc Nephrol 2004, 15:2457-2461. 10.1097/01.ASN.0000135972.13396.6F, 15339995.
9. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993, 21:573-592.
10. Saito T. Abnormal lipid metabolism and renal disorders. Tohoku J Exp Med 1997, 181:321-337. 10.1620/tjem.181.321, 9163848.
11. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000, 1:507-537. 10.1146/annurev.genom.1.1.507, 11701639.
12. Blue ML, Williams DL, Zucker S, Khan SA, Blum CB. Apolipoprotein E synthesis in human kidney, adrenal gland, and liver. Proc Natl Acad Sci USA 1983, 80:283-287. 10.1073/pnas.80.1.283, 393357, 6572003.
13. Araki S, Koya D, Makiishi T. APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study. Diabetes Care 2003, 26:2416-2420. 10.2337/diacare.26.8.2416, 12882872.
14. Araki S, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS. APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes 2000, 49:2190-2195. 10.2337/diabetes.49.12.2190, 11118024.
15. Bruschi M, Catarsi P, Candiano G. Apolipoprotein E in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Kidney Int 2003, 63:686-695. 10.1046/j.1523-1755.2003.00777.x, 12631135.
16. Chowdhury TA, Dyer PH, Kumar S. Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM. Diabetes 1998, 47:278-280.
17. Eto M, Horita K, Morikawa A. Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet 1995, 48:288-292.
18. Feussner G, Wey S, Bommer J, Deppermann D, Grutzmacher P, Ziegler R. Apolipoprotein E phenotypes and hyperlipidemia in patients under maintenance hemodialysis. Hum Genet 1992, 88:307-312. 10.1007/BF00197265, 1733833.
19. Horita K, Eto M, Makino I. Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 1994, 107:203-211. 10.1016/0021-9150(94)90021-3, 7980694.
20. Kimura H, Suzuki Y, Gejyo F. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 1998, 31:666-673. 10.1053/ajkd.1998.v31.pm9531184, 9531184.
21. Roussos L, Ekstrom U, Ehle PN, Oqvist B, Floren CH. Apolipoprotein E polymorphism in 385 patients on renal replacement therapy in Sweden. Scand J Urol Nephrol 2004, 38:504-510. 10.1080/00365590410033443, 15841787.
22. Werle E, Fiehn W, Hasslacher C. Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. Diabetes Care 1998, 21:994-998. 10.2337/diacare.21.6.994, 9614620.
23. Liberopoulos E, Siamopoulos K, Elisaf M. Apolipoprotein E and renal disease. Am J Kidney Dis 2004, 43:223-233. 10.1053/j.ajkd.2003.10.013, 14750087.
24. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J Biol Chem 2001, 276:49142-49147. 10.1074/jbc.M104879200, 11579084.
25. Zeleny M, Swertfeger DK, Weisgraber KH, Hui DY. Distinct apolipoprotein E isoform preference for inhibition of smooth muscle cell migration and proliferation. Biochemistry 2002, 41:11820-11823. 10.1021/bi026202k, 12269825.
26. Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the apolipoprotein E system in man. Am J Hum Genet 1980, 32:339-347. 1686062, 7386461.
27. Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet 1981, 33:11-24. 1684875, 7468588.
28. Hsu CC, Kao WH, Coresh J. Apolipoprotein E and progression of chronic kidney disease. Jama 2005, 293:2892-2899. 10.1001/jama.293.23.2892, 15956634.
29. Corder EH, Saunders AM, Strittmatter WJ. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923. 10.1126/science.8346443, 8346443.
30. Tang MX, Stern Y, Marder K. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. Jama 1998, 279:751-755. 10.1001/jama.279.10.751, 9508150.
31. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. Jama 1994, 272:1666-1671. 10.1001/jama.272.21.1666, 7966894.
32. Liberopoulos EN, Miltiadous GA, Cariolou M, Kalaitzidis R, Siamopoulos KC, Elisaf MS. Influence of apolipoprotein E polymorphisms on serum creatinine levels and predicted glomerular filtration rate in healthy subjects. Nephrol Dial Transplant 2004, 19:2006-2012. 10.1093/ndt/gfh349, 15187200.
33. Rebeck GW, Kindy M, LaDu MJ. Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis 2002, 4:145-154.
34. Corder EH, Saunders AM, Risch NJ. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994, 7:180-184. 10.1038/ng0694-180, 7920638.
35. Mahley RW, Weisgraber KH, Innerarity TL, Rall SC. Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism. Jama 1991, 265:78-83. 10.1001/jama.265.1.78, 1845776.
36. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Series 1: Programs and Collections Procedures. Vital Health Stat 1994, 32:1-407.
37. Ezzati TM, Massey JT, Waksberg J, Chu A, Maurer KR. Sample design: Third National Health and Nutrition Examination Survey. Vital Health Stat 1992, 2:1-35.
38. Crawford DC, Sanders CL, Qin X. Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 2006, 114:2458-2465. 10.1161/CIRCULATIONAHA.106.615740, 17101857.
39. Lohr S. Sampling: Design and Analysis. 1999, Duxbury Press, Pacific Grove, CA.
40. NCHS Note for Correction of Serum Creatinine for NHANES III, NHANES 1999-2000, 2001-2002 and 2003-2004. , http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/general_%20note_for_ser um_creatinine.pdf
41. Levey AS, Coresh J, Greene T. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247-254.
42. Levey AS, Stevens LA, Schmid CH. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612. 2763564, 19414839.
43. Astor BC, Arnett DK, Brown A, Coresh J. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 2004, 43:836-845. 10.1053/j.ajkd.2003.12.047, 15112174.
44. Gunter E, Lewis B, Kocikowski S. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1998-1994. Atlanta, GA, Public Health Service Centers for Disease Control and Prevention, National Center for Environmental Health; Hyattsville, MD, National Center for Health Statistics 1996,
45. Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Laboratory Protocol. Hyattsville MUSDo
46. StataCorp Stata Statistical Software: Release 9. 2005, College Station, TX: StataCorp LP.
47. Gauderman W, Morrison J. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies. , http://hydra.usc.edu/gxe
48. Garcia-Closas M, Lubin JH. Power and sample size calculations in case-control studies of gene-environment interactions: comments on different approaches. American journal of epidemiology 1999, 149:689-692. 10.1016/S1047-2797(00)00074-0, 10206617.
49. Levey A, Stevens L, Schmid C. A New Formula to Estimate GFR from Serum Creatinine: Improved Accuracy and Updated Estimates of Prevalence of Chronic Kidney Disease in the United States. 2008,
50. Hsueh WC, Mitchell BD, Hixson JE, Rainwater DL. Effects of the ApoE polymorphism on plasma lipoproteins in Mexican Americans. Ann Epidemiol 2000, 10:524-531. 10.2337/diabetes.40.3.334, 11118932.
51. Shriver MD, Boerwinkle E, Hewett-Emmett D, Hanis CL. Frequency and effects of apolipoprotein E polymorphism in Mexican-American NIDDM subjects. Diabetes 1991, 40:334-337. 10.1093/ndt/15.12.1971, 1999275.
52. Haffner SM, Stern MP, Miettinen H, Robbins D, Howard BV. Apolipoprotein E polymorphism and LDL size in a biethnic population. Arterioscler Thromb Vasc Biol 1996, 16:1184-1188. 10.1046/j.1523-1755.1999.07107.x, 8792773.
53. Oda H, Yorioka N, Ueda C, Kushihata S, Yamakido M. Apolipoprotein E polymorphism and renal disease. Kidney Int Suppl 1999, 71:S25-27. 10.1053/ajkd.2002.34502, 10412731.
54. Eto M, Saito M, Okada M. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 2002, 40:243-251. 10.1093/ndt/15.12.1971, 12148096.
55. Hadjadj S, Gallois Y, Simard G. Lack of relationship in long-term type 1 diabetic patients between diabetic nephropathy and polymorphisms in apolipoprotein epsilon, lipoprotein lipase and cholesteryl ester transfer protein. Genetique de la Nephropathie Diabetique Study Group. Donnees Epidemiologiques sur le Syndrome d'Insulino-Resistance Study Group. Nephrol Dial Transplant 2000, 15:1971-1976. 10.1093/ndt/15.12.1971, 11096142.
56. Greenburg A. Primer on Kidney Diseases. 2001, Academic Press.